Sinonasal Undifferentiated Carcinoma.

Autor: Abdelmeguid AS; Department of Head and Neck Surgery, Division of Surgery, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit 1445, Houston, TX, 77030, USA.; Department of Otolaryngology Head and Neck Surgery, Faculty of Medicine, Mansoura University, Mansoura, Egypt., Bell D; Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Hanna EY; Department of Head and Neck Surgery, Division of Surgery, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit 1445, Houston, TX, 77030, USA. EYHanna@mdanderson.org.
Jazyk: angličtina
Zdroj: Current oncology reports [Curr Oncol Rep] 2019 Feb 26; Vol. 21 (3), pp. 26. Date of Electronic Publication: 2019 Feb 26.
DOI: 10.1007/s11912-019-0776-4
Abstrakt: Purpose of Review: To provide a comprehensive review of the literature highlighting the recent advances in the diagnosis and management of sinonasal undifferentiated carcinoma (SNUC) RECENT FINDINGS: SNUC usually presents at advanced stage and the prognosis is usually poor with high rates of locoregional recurrence and tendency to metastasize. Special attention should be made in differentiating SNUC from other sinonasal malignancies in order to guide the appropriate treatment accordingly. Multimodality treatment is usually recommended for treating SNUC. The use of neoadjuvant chemotherapy may be associated with improved outcome and can be used to guide the subsequent treatment selection. Despite the recent advances in chemotherapeutic agents, radiation techniques, and surgical approaches, the prognosis and survival outcomes of SNUC remain poor. The addition of induction chemotherapy to the treatment approach followed by definitive local therapy needs to be further studied as it might improve the outcome.
Databáze: MEDLINE
Externí odkaz: